Age (n = 150) | - | 40.54±11.08 (n = 54) | 50.39±12.47 (n = 96) | - | −4.829 |
p < 0.001 |
Sex (n = 150) | male | 36(66.67) | 68(70.83) | 104 | 0.282 | 0.595 |
female | 18(33.33) | 28(29.17) | 46 | |||
wildtype | 17(32.08) | 69(75.82) | 86 | 26.649 | p < 0.001 | |
mutant | 36(67.92) | 22(24.18) | 58 | |||
non-codeletion | 23(51.11) | 55(85.94) | 78 | 15.746 | p < 0.001 | |
codeletion | 22(48.89) | 9(14.06) | 31 | |||
non-deletion | 38(100.00) | 20(80.00) | 58 | 5.745b | 0.017 |
|
deletion | 0(0.00) | 5(20.00) | 5 | |||
non-amplification | 8(66.67) | 45(65.22) | 53 | 0.054a | 0.817 | |
amplification | 4(33.33) | 24(34.78) | 28 | |||
chr7 gain/10 loss (n = 26) | negative | 10(83.33) | 13(92.86) | 23 | 0.552b | 0.457 |
positive | 2(16.67) | 1(7.14) | 3 | |||
Grade (n = 119) | high-grade | 6(16.22) | 70(85.37) | 76 | 52.828 | p < 0.001 |
low-grade | 31(83.78) | 12(14.63) | 43 | |||
WHO grade (n = 119) | WHO grade 2 | 26(70.27) | 4(4.88) | 30 | 62.664a | p < 0.001 |
WHO grade 3 | 5(13.51) | 8(9.76) | 13 | |||
WHO grade 4 | 6(16.22) | 70(85.37) | 76 | |||
Integrated histo-molecular diagnoses (n = 116) | Oligodendroglioma, IDH-mutant and 1p/19q-deleted | 17(45.95) | 7(8.86) | 24 | 41.238 | p < 0.001 |
Astrocytoma, IDH-mutant | 15(40.54) | 12(15.19) | 27 | |||
Glioblastoma, IDH-wildtype | 5(13.51) | 60(75.95) | 65 |
Panecrosis | |||||
Tumor- |
< 0.001 | 0.824 (0.711 ~0.936) | 0.94 | 0.625 | 0.07 |
Edema- |
0.031 |
0.655 (0.527 ~ 0.783) | 0.833 | 0.46 | 0.03 |
Tumor- |
< 0.001 | 0.891 (0.788 ~ 0.995) | 0.96 | 0.833 | 0.17 |
Edema- |
0.002 |
0.728 (0.613 ~ 0.842) | 0.34 | 1 | 0.16 |
Tumor- |
< 0.001 | 0.872 (0.761 ~ 0.983) | 0.833 | 0.86 | 2.48 |
Tumor- |
< 0.001 | 0.899 (0.803 ~ 0.996) | 1 | 0.75 | 0.07 |
Imnecrosis | |||||
Tumor- |
< 0.001 | 0.856 (0.772 ~ 0.939) | 0.877 | 0.757 | 0.08 |
Tumor- |
< 0.001 | 0.929 (0.872 ~ 0.986) | 0.892 | 0.919 | 0.17 |
Edema- |
0.005 |
0.667 (0.558 ~ 0.776) | 0.708 | 0.595 | 0.06 |
Tumor- |
< 0.001 | 0.914 (0.857 ~ 0.971) | 0.946 | 0.831 | 2.74 |
Tumor- |
< 0.001 | 0.909 (0.844 ~ 0.974) | 0.8 | 0.946 | 0.13 |
WHO CNS grade 4 | female | 63 | 2.5 | 1 | 0 | 0 | NA | NA | Astrocytoma, IDH-mutant | |
CNS WHO grade 4 | female | 55 | 20 | 0 | 0 | NA | 0 | NA | Glioblastoma, IDH-wildtype | |
CNS WHO grade 2 | female | 36 | NA | 1 | 1 | 0 | NA | NA | Oligodendroglioma, IDH-mutant and 1p/19q-deleted | |
NA | female | 34 | NA | 1 | NA | NA | NA | NA | IDH-mutation, NOS | |
CNS WHO grade 4 | male | 64 | 5 | 0 | 0 | NA | 1 | NA | Glioblastoma, IDH-wildtype | |
CNS WHO grade 2 | male | 40 | 25 | 1 | 0 | 0 | NA | NA | Astrocytoma, IDH-mutant | |
CNS WHO grade 3 | female | 55 | 60.06 | 1 | 1 | 0 | NA | NA | Oligodendroglioma, IDH-mutant and 1p/19q-deleted | |
CNS WHO grade 2 | male | 26 | 5.39 | 1 | 0 | 0 | 0 | 0 | Astrocytoma, IDH-mutant | |
NQ | male | 40 | 7.19 | 0 | 0 | NA | 0 | NA | IDH-wildtype, NOS | |
NA | male | 28 | 19.68 | 0 | 0 | NA | 0 | 0 | IDH-wildtype, NOS | |
CNS WHO grade 3 | male | 26 | 34.42 | 1 | 0 | 0 | NA | NA | Astrocytoma, IDH-mutant |